• en
  • sr


+381 (0) 11 20 70 801
kontakt@k2d3.com

Poruči ONLINE

Studije

Preparat K2D3 je proizveden od najkvalitetnijih sirovina najvišeg stepena čistoće.

K2D3 sadrži MK-7, superiornu formu vitamina K2 sa najvećom iskoristljivošću u organizmu. Ova forma vitamina K2 se u krvi zadržava 8 do 10 puta duže od drugih oblika vitamina K2. Na taj način, K2D3 obezbeđuje telu optimalnu količinu vitamina K2 i pogodan je za doziranje jednom dnevno.  Smatra se da je ovakva primena efikasnija i komfornija.

K2D3 izrađuje se u skladu sa najvišim proizvodnim standardima.

AbelaPharmLogoAbela Pharm je jedina je kompanija u Srbiji koja poseduje internacionalni GMP sertifikat za razvoj, registraciju, upravljanje, obezbeđenje kvaliteta i proizvodnju dijetetskih suplemenata.

Poštovanjem Dobre proizvođačke prakse (GMP) i HACCP principa, Abela Pharm osigurava da samo najkvalitetniji proizvodi budu isporučeni pod imenom K2D3.

Preparat je odobren od strane Farmaceutskog fakulteta i Ministarstva zdravlja, i redovno prolazi ispitivanja i kontrole kvaliteta.

Studije K2D3

  1. Association between vitamin K intake from fermented soybeans, natto, and bone mineral density in elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study, Y. Fujita & M. Iki & J. Tamaki & K. Kouda & A. Yura & E. Kadowaki & Y. Sato & J.-S. Moon & K. Tomioka & N. Okamoto & N. Kurumatani, Osteoporos Int (2012) 23:705–714
  2. Bone quality and vitamin K2 in type 2 diabetes: Review of preclinical and clinical studies, Jun Iwamoto, Yoshihiro Sato, Tsuyoshi Takeda, and Hideo Matsumoto, Nutrition Reviews vol. 69 issue 3 March 2011. p. 162-167
  3. Calcium and vitamin D intake by postmenopausal women with osteoporosis in Spain: an observational calcium and vitamin D intake (CaVIT) study, Tao Fan, Gonzalo Nocea, Ankita Modi, Leah Stokes, Shuvayu S Sen, Global Outcomes Research, Merck & Company, Whitehouse Station, NJ, USA; Department of Outcomes Research, Merck, Sharp and Dohme Spain, Madrid, Spain; 3Global Human Health, Outcomes Research, Merck & Company, Whitehouse Station, NJ, USA
  4. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Booth SL, Tucker KL, Chen H, et al. Am J Clin Nutr. 2000;71:1201–1208.
  5. Effect of low dose vitamin K2 (MK-4) supplementation on bio-indices in postmenopausal Japanese women, Koitaya N, Ezaki J, Nishimuta M, Yamauchi J, Hashizume E, Morishita K, Miyachi M, Sasaki S, Ishimi Y, Nutritional Epidemiology Program, National Institute of Health and Nutrition, 1-23-1, Toyama, Shinjyuku-ku, Tokyo 162-8636, Japan.
  6. Intake of fermented soybeans, natto, is associated with reduced bone loss in postmenopausal women: Japanese Population-Based Osteoporosis (JPOS) Study. Ikeda Y, Iki M, Morita A, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H (2006) J Nutr 136:1323–8
  7. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women Osteoporos. M. H. J. Knapen, L. J. Schurgers, C. Vermeer , Int. 2007, 18, 963-972
  8. Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis. Ebina K, Shi K, Hirao M, Kaneshiro S, Morimoto T, Koizumi K, Yoshikawa H, Hashimoto J. Department of Orthopaedics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  9. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG), Nobuhiro Sasaki • Eiji Kusano • Hideaki Takahashi, Yasuhiro Ando • Kazuki Yano • Eisuke Tsuda, Yasushi Asano
  10. Vitamin K intake and hip fractures in women: a prospective study. Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA. Am J Clin Nutr. 1999;69:74–79.
  11. Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) Dialysis Study Investigators. J Bone Miner Res. 2012 Nov;27(11):2271-8. doi: 10.1002/jbmr.1677. Fusaro M, Noale M, Viola V, Galli F, Tripepi G, Vajente N, Plebani M, Zaninotto M, Guglielmi G, Miotto D, Dalle Carbonare L, D’Angelo A, Naso A, Grimaldi C, Miozzo D, Giannini S, Gallieni M;
  12. Vitamin K Treatment Reduces Undercarboxylated Osteocalcin but Does Not Alter Bone Turnover, Density, or Geometry in Healthy Postmenopausal North American Women, Neil Binkley,1 Judith Harke,1 Diane Krueger,1 Jean Engelke,1 Nellie Vallarta-Ast,1 Dessa Gemar,1, Mary Checovich,1 Richard Chappell,2 and John Suttie3, JOURNAL OF BONE AND MINERAL RESEARCH, Volume 24, Number 6, 2009
  13. Vitamin K: Novel molecular mechanisms of action and its roles in osteoporosis, Kotaro Azuma, Yasuyoshi Ouchi1 and Satoshi Inoue, Departments of Geriatric Medicine and Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, and Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical School, Saitama, Japan
  14. Vitamin K status of healthy Japanese women: age-related vitamin K requirement for -carboxylation of osteocalcin1–3, Naoko Tsugawa, Masataka Shiraki, Yoshitomo Suhara, Maya Kamao, Kiyoshi Tanaka, and Toshio Okano, American Journal of Clinical Nutrition
  15. Vitamin K1 intake is associated with higher bone mineral density and reduced bone resorption in early postmenopausal Scottish women: no evidence of gene-nutrient interaction with apolipoprotein E polymorphisms1–4, Helen M Macdonald, Fiona E McGuigan, Susan A Lanham-New, William D Fraser, Stuart H Ralston, and David M Reid
  16. Vascular Calcification in Middle Age and Long-Term Risk of Hip Fracture: The Framingham Study†, Elizabeth J Samelson PhD1,2,*, L Adrienne Cupples3, Kerry E Broe1, Marian T Hannan1,2, Christopher J O’Donnell4,Douglas P Kiel1,2
  17. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. Morishita M, Nagashima M, Wauke K, Takahashi H, Takenouchi K. Department of Joint Disease and Rheumatism, Nippon Medical School, Tokyo, Japan.
  18. Osteocalcin: Skeletal and Extra-Skeletal Effects, Anna Neve, Addolorata Corrado, and Francesco Paolo Cantatore*, Department of Medical and Surgical Sciences, Rheumatology Clinic, University of Foggia, Foggia, Italy
  19. Osteoporosis and vitamin K intake, Robert E Olson, American Journal of Clinical Nutrition
  20. Relationships between undercarboxylated osteocalcin and vitamin K intakes, bone turnover, and bone mineral density in healthy women, Mika Yamauchi a, Toru Yamaguchi a,*, Kiyoko Nawata a,b, Shin Takaoka a, Toshitsugu Sugimoto , a Internal medicine 1, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo-city, Shimane 693-8501, Japan, b Department of Health and Nutrition, The University of Shimane, Junior College, Matsue Campus, 7-24-2 Himenogi, Matsue-city, Shimane 690-0044, Japan
  21. Review Article Osteoporosis treatment: Focus on safety, Ian R. Reid , Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
  22. Serum level of under-carboxylated osteocalcin and bone mineral density in early menopausal Norwegian women. Emaus N, Nguyen ND, Almaas B, Berntsen GK, Center JR, Christensen M, Gjesdal CG, Grimsgaard AS, Nguyen TV, Salomonsen L, Eisman JA, Fønnebø VM. Department of Health and Care Sciences, Faculty of Health Sciences, University of Tromsø, 9037, Tromsø, Norway
  23. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women M. H. J. Knapen & N. E. Drummen & E. Smit & C. Vermeer & E. Theuwissen, Osteoporos Int 2013
  24. Treatment with vitamin k(2) combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells., Saito E, Wachi H, Sato F, Sugitani H, Seyama Y., Department of Clinical Chemistry, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Japan.
  25. Yaegashi Y, Onoda T, Tanno K, Kuribayashi T, Sakata K, Orimo H. Association of hip fracture incidence and intake of calcium, magnesium, vitamin D, and vitamin K. Eur J Epidemiol.2008;23:219–225.

Studije K2D3 Junior

  1. Uloga vitamina K2 i D3 u zdravlju dečjih kostiju
    Dobro je poznato da svakodnevna suplementacija vitaminom K2 pomaže da se poboljša gustina kostiju (BMD), značajno smanji gubitak koštane mase, i poboljša jačina kostiju. Na ovaj način vitamin K2 značajno doprinosi smanjenju rizika od preloma kod odraslih osoba.
    Nova istraživanja su pokazala vezu između vitamina K2 i mineralizacije kostiju kod dece. Studije koje su obuhvatile i zdravu i bolesnu decu pokazuju da deficit vitamina K2 kod dece postoji, ali takođe potvrđuju i da se suplementacija vitaminom K2 pokazala kao efikasno rešenje.
  2. Studija 1 – Britanska studija je poredila unos vitamina K kod 4.599 četvorogodišnjaka rođenih 1950. godine i 307 dece rođene 1990. godine.
    Rezultati su pokazali da je unos vitamina K bio značajno veći 1950. godine, a autori su zaključili da bi upravo ovo moglo da utiče na zdravlje kostiju i srca u kasnijem životnom dobu.
    Prynne CJ, Thane CW, Prentice A, Wadsworth ME. Intake and sources of phylloquinone (vitamin K (1)) in 4-year-old British children: comparison between 1950 and the 1990s. Public Health Nutr. 2005 Apr; 8(2):171-80.
  3. Studija 2 – Rezultati su pokazali da je nivo vitamina K, u korelaciji sa povećanjem gustine kostiju (BMD).
    Evropska studija je istraživala odnos između osteokalcina, gustine kostiju i biohemijskih markera koštanog prometa. Ispitivane su 223 zdrave devojčice u uzrastu od 11-12 godina koji prati dinamičan razvoj kostiju.
    O‘Connor E, Mølgaard C, Michaelsen KF, Jakobsen J, Lamberg-Allardt CJ, Cashman KD. Serum percentage
    undercarboxylated osteocalcin, a sensitive measure of vitamin K status, and its relationship to bone health indices in Danish girls. Br J Nutr. 2007 Apr; 97 (4):661-6.
  4. Studija 3 – Rezultati su pokazali da je visok nivo vitamina K u krvi i nizak nivo neaktiviranog osteokalcina, povezani sa manjom razgradnjom kostiju.
    Još jedna studija je ispitivala 245 zdravih devojčica uzrasta od 3-16 godina. Ispitivano je da li su svakodnevni unos vitamina K i njegovi markeri u korelaciji sa količinom minerala u kostima (BMC) i koštanom resorpcijom. Studija je rađena u periodu od 4 godine.
    Kalkwarf HJ, Khoury JC, Bean J, Elliot JG. Vitamin K, bone turnover, and bone mass in girls. Am J Clin Nutr. 2004 Oct; 80 (4):1075-80.
  5. Studija 4 – Ova pilot studija je pokazala da je kombinacija vitamina K2 i D3 očigledno ima pozitivan efekat na gustinu kostiju (BMD) dece sa TOSP.
    Jednogodišnja pilot studija je istraživala efekte suplementacije vitaminom K2 (50 mg) i vitaminom D (5 mg). U studiji je učestvovlalo 20-oro dece sa TOSP (poremećajem krvi – talasemijom), koji može da dovede do osteopenije i osteoporoze. Rezultati su pokazali značajno poboljšanje gustine kostiju (BMD) u području lumbalnog dela kičme, naročito u prepubertetskog grupi.
    Ozdemir MA, Yilmaz K, Abdulrezzak U, Muhtaroglu S, Patiroglu T, Karakukcu M, Unal E. The efficacy of vitamin K2 and calcitriol combination on thalassemic osteopathy. J Pediatr Hematol Oncol. 2013 Nov; 35 (8):623-7.
  6. Studija 5 – Istraživači su zaključili da suplementacija vitaminom K2 povećava koncentraciju ovog vitamina u krvi i povećava aktivaciju osteokalcina kod zdrave, prepubertetske dece.
    Rađena je i dvostruko slepa, randomizovana, placebo-kontrolisana studija u kojoj su zdrava deca u predpubertetu dobijala 45 mcg vitamina K2 dnevno. Studija je trajala 8 nedelja. Mereni su neaktivirani osteokalcin (ucOC) i aktivirani osteokalcin (COC), kao i njihov međusobni odnos (UCR).
    Rezultati su pokazali da se povećanjem unosa vitamina K2, smanjuje koncentracija neaktivnog osteokalcina (ucOC) i poboljšava UCR. Nije bilo značajnih promena u placebo grupi.
    Van Summeren MJ, Braam LA, Lilien MR, Schurgers LJ, Kuis W, Vermeer C. The effect of menaquinone-7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children. Br J Nutr. 2009 Oct; 102 (8):1171-8.